Kyowa Kirin International (United Kingdom)

Recent papers from Kyowa Kirin International (United Kingdom)

1. Disease Trajectories and Lived Experiences of Patients with X-Linked Hypophosphatemia in Taiwan: A Qualitative StudyJBMR Plus · 2026
2. Real-World Effectiveness of Burosumab Versus Oral Phosphate and Active Vitamin D in Adults with X-Linked Hypophosphatemia (XLH): A 3-Year Follow-Up of the XLH Disease Monitoring ProgramJournal of Bone and Mineral Research · 2026
3. Empowering Medical Affairs Professionals in Their Critical Role in Integrated Evidence Generation PlanningPharmaceutical Medicine · 2026
4. Burden of Disease in Pediatric Tumor-Induced Osteomalacia: A Literature ReviewCalcified Tissue International · 2026
5. Real-world outcomes in patients with tumor-induced osteomalacia treated vs not treated with burosumabJournal of the Endocrine Society · 2026
6. Second interim analysis of the post-authorisation safety study (PASS) of burosumab in paediatric patients with X-linked hypophosphataemiaEuropean Journal of Endocrinology · 2026
7. Safety, tolerability, pharmacokinetics, and efficacy of burosumab in infants with X-linked hypophosphataemia: an open-label, multicentre, non-randomised studyThe Lancet Diabetes & Endocrinology · 2026
8. Real-world Effectiveness of Burosumab Across Age Groups: X-linked Hypophosphatemia (XLH) Disease Monitoring ProgramThe Journal of Clinical Endocrinology & Metabolism · 2026
9. Real-world Impact of Treatment on Growth in Children With X-Linked HypophosphatemiaThe Journal of Clinical Endocrinology & Metabolism · 2026
10. Health-related quality of life in French adults with X-linked hypophosphatemia: real-world data from the International XLH RegistryJBMR Plus · 2026
11. Pain Medication Use in Patients With X-Linked Hypophosphatemia Treated With Burosumab: a Retrospective Real-world StudyJBMR Plus · 2026
12. Adolescents’ experience of living with X-linked hypophosphataemia (XLH): a mixed-methods analysis of those who continued and discontinued burosumab treatment after end of skeletal growthOrphanet Journal of Rare Diseases · 2026
13. Psychometric Evaluation of Worst Pruritus Numeric Rating Scale in Adults With Moderate-to-Severe Atopic DermatitisDermatology and Therapy · 2026
14. Psychometric Evaluation of Skin Pain and Sleep Disturbance Numeric Rating Scales in Moderate-to-Severe Atopic DermatitisDermatology and Therapy · 2026
15. Delayed diagnosis of X-linked hypophosphatemia in the absence of family history: a global unmet needJBMR Plus · 2025
16. Real-World Effectiveness of Burosumab in Adults with X-Linked Hypophosphataemia (XLH) in the UKCalcified Tissue International · 2025
17. Advancing Patient Evidence in XLH (APEX): Baseline analysis of a global data unification programBone · 2025
18. Novel tetravalent bispecific antibody, PSMA/TRAIL‑R2 REGULGENT™, induces selective tumor cell apoptosis without hepatotoxicityOncology Reports · 2025
19. Increased lifelong burden of comorbidities without increased early mortality in hereditary hypophosphatemia: A Danish register studyJBMR Plus · 2025
20. Rocatinlimab: A Novel T-Cell Rebalancing Therapy Targeting the OX40 Receptor in Atopic DermatitisDermatology and Therapy · 2025